Remarkably, the use of second-generation insulin analogs (semaglutide and tirzepatide) may serve as a valid adjunct to closed-loop insulin therapy by preventing or treating excess body weight and by enhancing the glycemic and metabolic benefits of AID systems in patients with T1D and comorbid overweight/obesity. The gene discussed is INS; the disease is Obesity.